Checkpoint Therapeutics (NASDAQ:CKPT) Announces Quarterly Earnings Results

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47), Zacks reports.Checkpoint Therapeutics Stock Up 0.2 %CKPT traded up $0.01 during trading hours on Friday, hitting $4.04. 522,554 shares of the company's stock were exchanged, compared to its average volume of 1,124,079. The stock has a market cap of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50. The stock's 50-day moving average is $3.32 and its two-hundred day moving average is $3.25. Analyst Ratings ChangesCKPT has been the topic of a number of research analyst reports. HC Wainwright restated a "neutral" rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital reissued a "hold" rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, D. Boral Capital restated a "buy" rating and issued a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.Read Our Latest Stock Report on CKPTInsider Buying and Selling at Checkpoint TherapeuticsIn other Checkpoint Therapeutics news, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the transaction, the chief financial officer now owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares of the company's stock, valued at approximately $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,674 shares of company stock worth $336,011. Insiders own 2.10% of the company's stock. About Checkpoint Therapeutics (Get Free Report)Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.Read MoreFive stocks we like better than Checkpoint TherapeuticsInvesting in Commodities: What Are They? How to Invest in ThemMarketBeat Week in Review – 03/24 - 03/28A Deeper Look at Bid-Ask SpreadsShould You Buy UPS Stock Now? Deep Dive Into Its 5-Year LowDo ETFs Pay Dividends? What You Need to Know4 Healthcare Stocks With Massive Gains—and More to ComeThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Checkpoint Therapeutics Right Now?Before you consider Checkpoint Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.While Checkpoint Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here